Palestinian National Public Health Institute established with support from Norway

The Norwegian Government is funding a project to establish a Palestinian National Institute of Public Health. A Memorandum of Understanding was signed yesterday by Salam Fayyad, Prime Minister of the Palestinian National Authority, and Jonas Gahr Støre, Norwegian Minister for Foreign Affairs.

Successful meningococcal vaccine in Africa

MenAfriVac is a vaccine developed by the international "Meningitis Vaccine Project" (MVP) to eliminate epidemics caused by serogroup A meningococci in African countries south of the Sahara. The vaccine was introduced in Burkina Faso, Mali and Niger in December 2010. The Norwegian Institute of Public Health (NIPH) is organising a large study in Burkina Faso to assess the vaccine’s efficacy.


Read more [20.09.2011]

Collaboration in India for rotavirus vaccine

Why are some oral vaccines less effective in low income countries than in wealthier countries? The Norwegian Institute of Public Health is collaborating with researchers in India to find the answer.


Read more [16.06.2011]

WHO Collaborating Centre for Reference and Research on Meningococci

Meningococcal disease constitutes an enormous public health burden, especially in sub-Saharan Africa where large scale epidemics occur. The World Health Organization (WHO) is committed to eliminating meningococcal disease as a public health problem. The Norwegian Institute of Public Health (NIPH), which has been an appointed WHO Collaborating Centre for Reference and Research on Meningococci since 1991, contributes to this task.
Read more [19.04.2011]

New meningitis vaccine to be launched in Burkina Faso

In December 2010, MenAfriVac^TM, a new affordable vaccine for serogroup A meningococcal meningitis will be introduced in Burkina Faso. MenAfriVac has the potential to significantly reduce disease and mortality in sub-Saharan Africa and eliminate devastating epidemics.
Read more [30.11.2010]

Norwegian Institute of Public Health receives $100,000 Grand Challenges Explorations Grant for innovative global health research

The Norwegian Institute of Public Health has announced that it has received a US $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Dr Carol Holm-Hansen titled “TB Rapid Test (TBRT) Project.” 

ENGAGE/CSG/P3G Summer Institute: ”Genetics, Ethics and Clinical Translation” 22-25th June 2010, The Netherlands

This four day intensive course is designed for professionals actively involved in biobanking who want to learn more about the ethical, legal and societal implications of the translation of epidemiological results from genetic and genomic research to clinical practice.
Read more [03.03.2010]

Collaboration with Arkhangelsk: Andrej Grjibovski appointed Director at the International School of Public Health in Arkhangelsk

Andrej Grjibovski has been appointed Director of the International School of Public Health in Arkhangelsk (ISPHA). Grjibovski is a medical doctor and works in the Department of Infectious Disease Control at the Norwegian Institute of Public Health.
Read more [19.01.2009]

Fractional dose of scarce meningitis vaccine may be effective in outbreak control

One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa.

10 years of collaboration with neighbouring countries

Better knowledge, better health surveillance - better infectious disease control

In 1998 the Norwegian Institute of Public Health began a co-operation with the Baltic countries and Russia. This was part of the project "Infectious disease control in the Barents and Baltic Sea Regions 1998-2001", funded by the Nordic Council of Ministers, the Swedish Institute for Infectious Disease Control and the Norwegian Institute of Public Health. Since 1999, the co-operation with neighbouring countries has been funded by the Norwegian Barents Health Programme with contributions from the Norwegian Institute of Public Health and partners.